MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

MDT

96.91

-0.67%↓

A

147.87

-0.47%↓

VEEV

232.45

-3%↓

HQY

84.34

-10.55%↓

PHR.US

17.13

-0.23%↓

Search

Cytek Biosciences Inc

Suletud

SektorTervishoid

5.8 6.62

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.68

Max

5.98

Põhinäitajad

By Trading Economics

Sissetulek

105K

-5.5M

Müük

6.7M

52M

Aktsiakasum

-0

Kasumimarginaal

-10.476

Töötajad

692

EBITDA

6.4M

-4.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+13.63% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

26. veebr 2026

Turustatistika

By TradingEconomics

Turukapital

165M

666M

Eelmine avamishind

-0.82

Eelmine sulgemishind

5.8

Uudiste sentiment

By Acuity

17%

83%

33 / 370 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Cytek Biosciences Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. jaan 2026, 23:54 UTC

Market Talk

CBA Could Underperform Again in 2026 -- Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Weaker Yen -- Market Talk

12. jaan 2026, 23:43 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

12. jaan 2026, 23:18 UTC

Omandamised, ülevõtmised, äriostud

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12. jaan 2026, 21:56 UTC

Market Talk

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. jaan 2026, 21:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12. jaan 2026, 20:54 UTC

Tulu

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12. jaan 2026, 20:48 UTC

Market Talk

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12. jaan 2026, 20:33 UTC

Market Talk

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12. jaan 2026, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12. jaan 2026, 19:39 UTC

Market Talk

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Gold and Silver Set New Records on Fed Probe -- Market Talk

12. jaan 2026, 19:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

12. jaan 2026, 19:33 UTC

Market Talk

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12. jaan 2026, 19:24 UTC

Omandamised, ülevõtmised, äriostud

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12. jaan 2026, 19:22 UTC

Omandamised, ülevõtmised, äriostud

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12. jaan 2026, 18:21 UTC

Omandamised, ülevõtmised, äriostud

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12. jaan 2026, 18:20 UTC

Omandamised, ülevõtmised, äriostud

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12. jaan 2026, 18:19 UTC

Market Talk

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12. jaan 2026, 18:16 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. jaan 2026, 18:09 UTC

Market Talk

Baidu's Outlook Bodes Well For Shares -- Market Talk

12. jaan 2026, 18:01 UTC

Omandamised, ülevõtmised, äriostud

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12. jaan 2026, 18:00 UTC

Market Talk

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Cytek Biosciences Inc Prognoos

Hinnasiht

By TipRanks

13.63% tõus

12 kuu keskmine prognoos

Keskmine 6.17 USD  13.63%

Kõrge 7.5 USD

Madal 5 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Cytek Biosciences Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

3 ratings

2

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

3.7 / 3.8Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Sentiment

By Acuity

33 / 370 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Cytek Biosciences Inc

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils. In addition, it offers automated micro-sampling system and automated sample loader system, an automated loaders to integrate seamlessly into the aurora and northern lights systems; SpectroFlo software that provides intuitive workflow from quality control to data analysis for aurora and northern lights systems; and customer support tools. The company serves pharmaceutical and biopharma companies, academic research centers, and clinical research organizations. It distributes its products through direct sales force and support organizations in North America, Europe, China, and the Asia-Pacific regions; and through distributors or sales agents in European, Latin American, and the Middle Eastern countries. The company was formerly known as Cytoville, Inc. and changed its name to Cytek Biosciences, Inc. in August 2015. Cytek Biosciences, Inc. was founded in 1992 and is headquartered in Fremont, California.
help-icon Live chat